Healthpeak and Hines Announce a Strategic Partnership on the Cambridge Point Mixed-Use Development in Cambridge, Massachusetts
Hines will lead the residential development in coordination with Healthpeak as master developer. Hines, with its partners, will capitalize the residential developments and intends to commence construction on the first residential building within the first 12 months following receipt of entitlements, which is anticipated in the second half of 2026.
Situated adjacent to the MBTA Rapid Transit Rail Station in the Alewife neighborhood, Cambridge Point is a 40-acre master plan that has total development potential of up to five million square feet. The project is anticipated to include multifamily residential units, research and lab space, and community-oriented ground-floor neighborhood retail uses. The pedestrian-oriented district will be defined by a highly walkable retail corridor, an extensive green open space network connecting Fresh Pond and Alewife Brook Reservation, and publicly beneficial infrastructure, including a pedestrian bridge to connect the community directly to the MBTA red line with a short ride to Kendall Square and South Station.
'We are thrilled to welcome Hines as a key partner in realizing our long-term vision for Cambridge Point,' shared Kelvin Moses, Healthpeak's Chief Financial Officer. He continued, 'Hines' reputation of delivering exceptional mixed-use and residential communities in urban centers aligns seamlessly with our commitment to quality and community impact. At Healthpeak, our real estate advances health and innovation—and with approximately 60 million square feet under management nationwide, we're deepening our investment in Cambridge with a long-term vision of contributing to a vibrant, mixed-use district.'
'Hines has a deep-rooted history in the Boston area, including our work at Fuse Cambridge in Alewife, and we're proud to partner with Healthpeak to continue shaping the community's built environment,' said Sarah Hawkins, Senior Managing Director and head of Hines' U.S. East market. 'Our goal is to deliver housing that will integrate innovation, intentional design, and a robust sense of place, reflecting the values of Cambridge for generations.'
Hines has been invested in the Greater Boston market for over 40 years, with nearly $3 billion in existing properties and active developments, including the approximately two million square feet mixed-use project, South Station Tower, along with multiple multifamily and industrial developments.
Cambridge Point represents the final large-scale development opportunity in Cambridge. It builds on Healthpeak's existing footprint in the region, where the company is already the largest commercial property owner in West Cambridge. The district is uniquely positioned to serve as a new gateway to Greater Boston's life sciences ecosystem, combining research, residential, and retail uses into one cohesive, transit-oriented environment. The master plan is expected to be built over multiple phases, including more than seven acres of publicly beneficial open space, streetscape improvements, active retail corridors, and green building strategies in alignment with Healthpeak's corporate responsibility objectives.
'Cambridge Point aligns Healthpeak's core values through community development—it's about shaping a place where people can live healthy lives, establish connections, innovate, and thrive,' said Scott Bohn, Chief Development Officer and Head of Lab at Healthpeak. 'Through our collaboration with Hines, we can contribute positively to the neighborhood in ways that reflect the values of the Cambridge community and support its ongoing growth as a global hub for innovation and discovery.'
ABOUT HEALTHPEAK PROPERTIES
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate for healthcare discovery and delivery. For more information regarding Healthpeak, visit www.healthpeak.com.
ABOUT HINES
Hines is a leading global real estate investment manager. We own and operate $90.1 billion¹ of assets across property types and on behalf of a diverse group of institutional and private wealth clients. Every day, our 5,000 employees in 30 countries draw on our 68-year history to build the world forward by investing in, developing, and managing some of the world's best real estate. To learn more, visit www.hines.com and follow @Hines on social media.
¹Includes both the global Hines organization and RIA AUM as of December 31, 2024.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 minutes ago
- Business Wire
PPG Board of Directors approves dividend increase to 71 cents per share
PITTSBURGH--(BUSINESS WIRE)--The Board of Directors of PPG (NYSE:PPG) today approved a 3-cents-per-share increase in the company's dividend, declaring a regular quarterly dividend of 71 cents per share, payable Sept. 12 to shareholders of record Aug 11. This marks the company's 508th consecutive dividend payment. Through the ongoing dedication and engagement of its workforce, the company has paid uninterrupted annual dividends since 1899. 'We are proud of PPG's long heritage of rewarding shareholders and are pleased to increase our dividend per share,' said Tim Knavish, PPG chairman and chief executive officer. 'This dividend growth reflects the strong confidence that PPG's Board has in the resiliency of our business and the strength and future growth of our company.' PPG: WE PROTECT AND BEAUTIFY THE WORLD® At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for more than 140 years. Through dedication and creativity, we solve our customers' biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $15.8 billion in 2024. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit The PPG Logo and We protect and beautify the world are registered trademarks of PPG Industries Ohio, Inc. CATEGORY Financial
Business Wire
7 minutes ago
- Business Wire
Ategrity Specialty Insurance Company Holdings to Announce Second Quarter 2025 Earnings on August 11, 2025
NEW YORK--(BUSINESS WIRE)--Ategrity Specialty Insurance Company Holdings (NYSE: ASIC) (the 'Company') announced today that it will release financial results for the second quarter ended June 30, 2025, after the market closes on Monday, August 11, 2025. These documents will be available on the Company's Investor Relations website at The Company will host a conference call to discuss its results on the same day, Monday, August 11, 2025, beginning at 5:00 p.m. Eastern Time. Interested parties may access the conference call via a live webcast, which can be accessed at or by visiting the Company's Investor Relations website. Please join the webcast at least 10 minutes before the scheduled start time. A replay of the event webcast will be available on the Company's Investor Relations website approximately two hours following the call, for a period of at least 30 days. About Ategrity Specialty Insurance Company Holdings Ategrity Specialty Insurance Company Holdings is a growing specialty insurance company dedicated to providing excess and surplus ('E&S') products to small to medium-sized businesses across the United States. We have built a proprietary underwriting platform that combines sophisticated data analytics with automated and streamlined processes to efficiently serve our clients and deliver long-term value to our stockholders. The small to medium-sized business market is characterized by large volumes of small-sized policies, and we believe our competitive edge lies in our ability to offer consistent, high-speed, and low-touch interactions that our distribution partners value. This advantage stems from our technology-driven method of standardizing, simplifying, and automating our transaction process, which we call productionized underwriting.
Yahoo
26 minutes ago
- Yahoo
Johnson & Johnson's Healthy 3.3%-Yielding Dividend Is a Very Safe Way to Make Passive Income
Key Points Johnson & Johnson continues to generate plenty of free cash flow to cover its dividend. The healthcare giant also maintains an elite balance sheet. With more growth ahead, it should have no trouble continuing to increase its high-yielding payout. 10 stocks we like better than Johnson & Johnson › Johnson & Johnson (NYSE: JNJ) has been an extremely reliable dividend stock for decades. The healthcare behemoth has raised its payment for 63 straight years, including by 4.8% earlier this year. That places it in the elite group of Dividend Kings -- companies with 50 or more consecutive years of increasing their dividend payouts. The healthcare company's payout currently yields 3.3%, more than double the S&P 500's (SNPINDEX: ^GSPC) dividend yield (near a record low at around 1.2%). That high-yielding payout is very healthy, making Johnson & Johnson a very safe way to collect dividend income. A financial fortress Johnson & Johnson recently reported its second-quarter financial results, which once again showcased the safety of its dividend payment. The healthcare company reported that it generated approximately $6.2 billion in free cash flow through the first half of this year, following investments of $6.7 billion in research and development (R&D). That was enough cash to cover its dividend payment, which has cost $6.1 billion year to date. While that might seem like a tight payout ratio, investors need not be concerned. Its free cash flow is only down slightly compared to the year-ago period, when it produced $7.5 billion through the first half of the year. Johnson & Johnson generated $20 billion in total free cash flow last year, easily covering its $11.8 billion dividend outlay. Meanwhile, Johnson & Johnson has one of the best balance sheets in the world. The company has a pristine AAA bond rating (one of only two companies in the world with elite credit). It ended the first quarter with $19 billion of cash and marketable securities on its balance sheet (nearly two years of dividend payments) against only $51 billion of debt. The $32 billion in net debt is a relatively small amount for a company with a roughly $375 billion market capitalization. Johnson & Johnson has maintained a strong balance sheet, even as it has deployed $15 billion in strategic inorganic growth opportunities over the past year, and more than $30 billion over the last two years. Investing heavily to grow Johnson & Johnson's robust financial profile enables it to invest heavily in R&D and M&A, driving growth of its innovative medicine and MedTech platforms. Last year, the company spent more than $17 billion in R&D (19.4% of its total sales). That made it one of the top R&D investors across all industries. Adding acquisitions and other inorganic investments, the company invested a whopping $50 billion in growth initiatives last year. Those growth investments are starting to pay off. "Our portfolio and pipeline position us for elevated growth in the second half of the year," commented CEO Joaquin Duato in the second-quarter earnings press release. As a result, the company boosted its annual revenue guidance by $2 billion (implying 5.4% growth for the full year) and tacked $0.25 per share to its adjusted earnings per share outlook, increasing the midpoint to $10.68. The company anticipates it will continue growing at a healthy pace over the next few years. By 2027, Johnson & Johnson expects that one-third of its MedTech sales will come from new products. Meanwhile, the company expects to launch more than 10 innovative medicine assets by 2030, with the potential to deliver over $5 billion in peak-year sales. The growth from these products will help to more than replace the lost sales from expiring patents, enabling the company to continue increasing revenue and free cash flow at healthy rates. It can also continue utilizing its fortress balance sheet to supplement its R&D efforts with strategic M&A opportunities as they arise. A very safe dividend stock Johnson & Johnson continues to showcase its elite ability to pay dividends. The healthcare company's high-yielding payout remains on rock-solid ground, even though its free cash flow is down through the first half of this year. With a fortress balance sheet and visible growth ahead, the company should have no problem continuing to increase its dividend at a healthy pace. As a result, it remains an extremely safe way to generate passive dividend income. Do the experts think Johnson & Johnson is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Johnson & Johnson make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,060% vs. just 179% for the S&P — that is beating the market by 881.02%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $679,653!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,046,308!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Matt DiLallo has positions in Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy. Johnson & Johnson's Healthy 3.3%-Yielding Dividend Is a Very Safe Way to Make Passive Income was originally published by The Motley Fool
